Neurodegeneration

Global Spatial Genomics & Transcriptomics Global Market Report 2023: Increasing Adoption of Spatial Genomics & Transcriptomics Analysis in Translational Research to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Software, Technology, Pharmaceutical, Health, Government, Cancer, Science and technology in Asia, Drug discovery, Research, End user, Biomarker, USD, Regenerative medicine, Neoplasm, Growth, Conditional sentence, Incidence, Spatial transcriptomics, Neurodegeneration, Translational research, Medicinal plants, Software

The "Global Spatial Genomics & Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Translational Research, Drug Discovery), End User, Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Spatial Genomics & Transcriptomics Market by Technique (Spatial Transcriptomics, Spatial Genomics), Product (Instruments, Consumables, Software), Application (Translational Research, Drug Discovery), End User, Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • Market growth is largely driven by the shift from strictly research applications to drug discovery & development for areas such as neurodegenerative diseases and cancer.
  • Spatial genomics and transcriptomics are also anticipated to address current unmet clinical needs in oncology, including the demand for predictive biomarkers of response.
  • Based on application, the spatial genomics and transcriptomics market is categorized into translational research and drug discovery & development.

X-Chem and Sironax Begin Neurodegenerative Disease Drug Discovery Research Partnership

Retrieved on: 
Thursday, January 5, 2023
Research, Neurology, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Research, Partnership, DEL, Library, Degenerative disease, Neurodegeneration, Chem, Medical imaging, Computer data storage

X-Chem , the global leader in DNA-encoded library (DEL) technology, today announces the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.

Key Points: 
  • X-Chem , the global leader in DNA-encoded library (DEL) technology, today announces the establishment of a research partnership with Sironax, in which X-Chem will leverage its powerful DEL platform to support Sironax’s drug discovery pipeline.
  • Through the collaboration, X-Chem will screen its unique DNA-encoded libraries against difficult-to-drug targets implicated in neurodegenerative disease to discover hits.
  • In turn, Sironax will prosecute these hits into transformational medicines for degenerative disease.

Oligomerix Announces Issuance of Key U.S. Patent for Lead Tau-Targeting Candidate OLX-07010 to Treat Neurodegenerative Diseases

Retrieved on: 
Thursday, January 5, 2023
Science, Neurology, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Patent, Neurodegeneration, MBA, Development, Discovery, Quinazolinone, Therapy, Dementia, AD, Caregiver, Pharmaceutical industry

“We are very pleased that the USPTO has issued this important patent allowing us to build on our existing patent estate in a thoughtful and strategic manner,” said William Erhardt, M.D., President and Head of Development & Operations at Oligomerix.

Key Points: 
  • “We are very pleased that the USPTO has issued this important patent allowing us to build on our existing patent estate in a thoughtful and strategic manner,” said William Erhardt, M.D., President and Head of Development & Operations at Oligomerix.
  • “With this patent in place, we have enhanced the value of our portfolio, including our lead candidate OLX-07010 which will begin first-in-human clinical trials soon.”
    According to the Alzheimer’s Association, more than 6.5 million Americans suffer from AD.
  • Furthermore, the current cost for AD is $321 billion and projected to be more than $1 trillion by 2050.
  • “The issuance of the ‘766 patent supports our continued work aimed at blocking tau self-association to prevent downstream damage associated with neurodegeneration and dementias,” said James Moe, Ph.D., MBA, CEO and Head of Discovery and Strategy at Oligomerix.

Global Minimally Invasive Surgical (MIS) Devices Market to Reach $42.4 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Surgery, Health, Medical Devices, Lung cancer, Abbott, Stomach, Competitive landscape, MicroPort, International Agency for Research on Cancer, The Cooper Companies, Food, MIS, COVID-19, Organic, RAS, USD, Top 40, Prostate, Olympus, CE, Research, Growth, Medtronic, KARL, Intuitive Surgical, Alpha Group Co., Ltd., US Foods, Boston Scientific, Minimally invasive procedure, Degenerative disease, BD, Hugot, Ageing, Liver, Incidence, CE marking, Prevalence, Neurodegeneration, Medical device, Dietary supplement, Medical imaging, Flowers, Cancer

The "Minimally Invasive Surgical (MIS) Devices - Market Insight, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Minimally Invasive Surgical (MIS) Devices - Market Insight, Competitive Landscape and Market Forecast - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global MIS devices market was valued at USD 28,873.25 million in 2021, growing at a CAGR of 7.38% during the forecast period from 2022 to 2027, in order to reach USD 42,499 million by 2027.
  • Minimally Invasive Surgical (MIS) Devices Market Dynamics:
    One of the key aspects driving the MIS devices market can be attributed to the surge in cancer incidence.
  • Various end-users who want to know more about the MIS devices market and latest technological developments in the MIS devices market.

Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas

Retrieved on: 
Wednesday, January 4, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Hoffmann-La Roche, Therapy, MD, Sale, Disease, Patient, Proteome, Roche, Autoimmunity, Doctor of Philosophy, Neurodegeneration, Pharmaceutical industry, Fine chemical, Belharra, Genentech

Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.

Key Points: 
  • Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.
  • The companies will collaborate employing Belharra’s proprietary platform to discover and develop small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune, and neurodegenerative diseases.
  • The company’s proprietary screening library enables Belharra scientists to identify any binding site, on any protein, in any conformational state, in any cell type.
  • “Partnering with early-stage companies like Belharra provides Genentech with yet another way to advance groundbreaking science to discover and develop medicines for patients with serious and life-threatening diseases.”

North America Probiotics Food and Cosmetics Market Report 2022: A $20 Billion Market by 2027 Featuring Kerry Group, Yakult Honsha, Probi, BioGaia, Nestle, BLIS, P&G, DuPont, ADM, Estee Lauder, Esse - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 4, 2023
Cosmetics, Vitamins, Supplements, Retail, Health, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, International Food Information Council, NBTY, Ageing, Cancer, Biotechnology, Blis Technologies, Procter & Gamble, Kerry Group, Research, Neurodegeneration, COVID-19, Skin, Inflammation, Food, Cosmetics, Vitamin, Enzyme, Probiotic, Acquisition, Growth, Functional food, Pride, Dietary supplement, Degenerative disease, DuPont, BioGaia, Mineral, ADM, Cosmetic, Snack, Human rights in Muslim-majority countries, Drink, Bottled water, Nestlé, Segment, Puritans

Multiple benefits to body and skin with the use of probiotics products and rising demand for nutritional food as compared to other medicated products are major growth drivers for the North America Probiotics Food and Cosmetics market.

Key Points: 
  • Multiple benefits to body and skin with the use of probiotics products and rising demand for nutritional food as compared to other medicated products are major growth drivers for the North America Probiotics Food and Cosmetics market.
  • Multiple global brands in the functional food and beverage sector have launched innovative probiotic-fortified products in the market helping the growth.
  • For instance, Farmi Piimatoostus Ltd. launched fermented buttermilk and a number of packaged snacks with probiotics.
  • Hansen, Nearly 48% of people in North America consume probiotics almost daily either in foods or supplements.

Ventus Therapeutics Nominates Potential First-in-Class cGAS Inhibitor VENT-03 as Inaugural Development Candidate in cGAS Franchise

Retrieved on: 
Wednesday, January 4, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Dermatomyositis, U.S. Department of Defense Strategy for Operating in Cyberspace, Therapy, Pain scale, NLRP3, Infant, Disease, Lupus, Novo Nordisk, Resolve, Human, Scleroderma, Neurodegeneration, Pharmaceutical industry, Ventus

Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today the nomination of a potential first-in-class cGAS inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.

Key Points: 
  • Ventus Therapeutics, Inc. , a biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to identify and develop differentiated small molecule therapeutics across a broad range of diseases, announced today the nomination of a potential first-in-class cGAS inhibitor, VENT-03, as the company’s first development candidate directed against cGAS.
  • This represents the third development candidate nominated in the past 12 months to Ventus’ pipeline, following the nominations of VENT-02, a brain-penetrant NLRP3 inhibitor, and VENT-01, a peripherally restricted NLRP3 inhibitor that is partnered with Novo Nordisk.
  • In disease-relevant preclinical studies, VENT-03 demonstrated robust in vivo pharmacodynamic activity and efficacy.
  • Given the highly validated role of the cGAS pathway as a driver of disease, we are now developing additional cGAS inhibitors to achieve the full potential of this attractive target in distinct therapeutic areas.”

Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

Retrieved on: 
Wednesday, January 4, 2023
Health, Other Health, Other Science, Research, Science, Pharmaceutical, Biotechnology, EXEL, Therapy, Cornell University, Neurodegeneration, Acquisition, Patient, Biology, Degenerative disease, Bristol Myers Squibb, Jazz Pharmaceuticals, Alexion Pharmaceuticals, Pharmaceutical industry, Genzyme, IND

Nuvig Therapeutics, Inc. , a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors.

Key Points: 
  • Nuvig Therapeutics, Inc. , a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors.
  • Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company’s Chief Scientific Officer.
  • Ms. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals.
  • Ms. Smith serves as a director on the Boards of Exelixis (Nasdaq: EXEL) and Stoke Therapeutics (Nasdaq: STOK).

Aruna Bio Announces Appointment of Mike Ryan to its Board of Directors

Retrieved on: 
Monday, December 19, 2022
Stroke, Traffic barrier, Neuroprotection, Bachelor of Engineering, University College Dublin, Acquisition, Mechanical engineering, Investment, IND, Strategic planning, Neurodegeneration, Management, Aruna

BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the appointment of Mike Ryan to its Board of Directors, effective immediately.

Key Points: 
  • BOSTON and ATHENS, Ga., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Aruna Bio, Inc., a leader in the development of neural exosome-based therapeutics for the treatment of neurodegenerative diseases, today announced the appointment of Mike Ryan to its Board of Directors, effective immediately.
  • "It is a pleasure to welcome Mike, an esteemed industry leader, to our Board of Directors," said Stephen From, Chief Executive Officer of Aruna.
  • Mr. Ryan is one of the Founder Directors of Irrus Investments, the largest angel investment syndicate in Ireland with an emphasis on life science companies.
  • Mr. Ryan holds a B.Eng in Mechanical Engineering and a Masters in Industrial Engineering from University College Dublin.

ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

Retrieved on: 
Tuesday, December 27, 2022
Science, Seniors, Biotechnology, Research, Pharmaceutical, Health, Consumer, Clinical Trials, University of Delaware, Clinical trial, PD, Insulin resistance, Central nervous system, Timeline of Genesis patriarchs, Nature Communications, Protein, Phosphoprotein, Research, Neurodegeneration, National Institute on Aging, DNA, Brain, Biomarker, NIA, Inflammation, Trial of the century, Metabolism, Tissue, Patient, Plasma, Seminal vesicles, Pathology, Neuron, University, Kinesiology, Aging Cell, NEV, Ageing, Human, Paper, ChromaDex, AD, RNA, Cell, Pharmaceutical industry, Medical imaging, Medical device, NEVS

The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.

Key Points: 
  • The study investigated whether NR would positively augment nicotinamide adenine dinucleotide (NAD+) levels and impact markers of neurodegenerative disease and insulin signaling in neuron-derived extracellular vesicles (NEVs) found in blood plasma.
  • NEVs are nano-sized particles that are released by neurons in the central nervous system, including the brain, and circulate in blood plasma.
  • The present study demonstrated that oral supplementation with NR significantly increased NAD+ levels in NEVs and attenuated neurodegenerative biomarkers including Aβ42, a biomarker for Alzheimer’s disease (AD).
  • Such results are promising and will set the foundation for further research evaluating NR supplementation in neurodegenerative disorders.